Bicuspid aortic valve (BAV) patients are conventionally not treated by transcathether aortic valve implantation (TAVI) because of anatomic constraint with unfavorable outcome. Patient-specific numerical simulation of TAVI in BAV may predict important clinical insights to assess the conformability of the transcathether heart valves (THV) implanted on the aortic root of members of this challenging patient population. We aimed to develop a computational approach and virtually simulate TAVI in a group of n.6 stenotic BAV patients using the self-expanding Evolut Pro THV. Specifically, the structural mechanics were evaluated by a finite-element model to estimate the deformed THV configuration in the oval bicuspid anatomy. Then, a fluid–solid interaction analysis based on the smoothed-particle hydrodynamics (SPH) technique was adopted to quantify the blood-flow patterns as well as the regions at high risk of paravalvular leakage (PVL). Simulations demonstrated a slight asymmetric and elliptical expansion of the THV stent frame in the BAV anatomy. The contact pressure between the luminal aortic root surface and the THV stent frame was determined to quantify the device anchoring force at the level of the aortic annulus and mid-ascending aorta. At late diastole, PVL was found in the gap between the aortic wall and THV stent frame. Though the modeling framework was not validated by clinical data, this study could be considered a further step towards the use of numerical simulations for the assessment of TAVI in BAV, aiming at understanding patients not suitable for device implantation on an anatomic basis.
Atlas-based analyses of patients with cardiovascular diseases have recently been explored to understand the mechanistic link between shape and pathophysiology. The construction of probabilistic atlases is based on statistical shape modeling (SSM) to assess key anatomic features for a given patient population. Such an approach is relevant to study the complex nature of the ascending thoracic aortic aneurysm (ATAA) as characterized by different patterns of aortic shapes and valve phenotypes. This study was carried out to develop an SSM of the dilated aorta with both bicuspid aortic valve (BAV) and tricuspid aortic valve (TAV), and then assess the computational hemodynamic of virtual models obtained by the deformation of the mean template for specific shape boundaries (i.e., ±1.5 standard deviation, σ). Simulations demonstrated remarkable changes in the velocity streamlines, blood pressure, and fluid shear stress with the principal shape modes such as the aortic size (Mode 1), vessel tortuosity (Mode 2), and aortic valve morphologies (Mode 3). The atlas-based disease assessment can represent a powerful tool to reveal important insights on ATAA-derived hemodynamic, especially for aneurysms which are considered to have borderline anatomies, and thus challenging decision-making. The utilization of SSMs for creating probabilistic patient cohorts can facilitate the understanding of the heterogenous nature of the dilated ascending aorta.
In ascending thoracic aortic aneurysms (ATAAs), aneurysm kinematics are driven by ventricular traction occurring every heartbeat, increasing the stress level of dilated aortic wall. Aortic elongation due to heart motion and aortic length are emerging as potential indicators of adverse events in ATAAs; however, simulation of ATAA that takes into account the cardiac mechanics is technically challenging. The objective of this study was to adapt the realistic Living Heart Human Model (LHHM) to the anatomy and physiology of a patient with ATAA to assess the role of cardiac motion on aortic wall stress distribution. Patient-specific segmentation and material parameter estimation were done using preoperative computed tomography angiography (CTA) and ex vivo biaxial testing of the harvested tissue collected during surgery. The lumped-parameter model of systemic circulation implemented in the LHHM was refined using clinical and echocardiographic data. The results showed that the longitudinal stress was highest in the major curvature of the aneurysm, with specific aortic quadrants having stress levels change from tensile to compressive in a transmural direction. This study revealed the key role of heart motion that stretches the aortic root and increases ATAA wall tension. The ATAA LHHM is a realistic cardiovascular platform where patient-specific information can be easily integrated to assess the aneurysm biomechanics and potentially support the clinical management of patients with ATAAs.
Transcatheter aortic valve implantation (TAVI) has become a standardized treatment for aortic valve stenosis, supported by computational modeling to enhance procedural planning. However, the credibility of TAVI simulations requires rigorous validation following regulatory standards. This study aims to perform a population-based validation of the structural and hemodynamic simulation performance of the SAPIEN 3 (S3) Ultra device by comparing computational predictions with clinical post-TAVI data, following the ASME V&V 40 framework. A patient-specific structural model followed by fluid–structure interaction was developed to simulate S3 deployment and then assess post-TAVI hemodynamics in 20 patients. Structural parameters (device diameters) and hemodynamic indices (effective orifice area, EOA, and transmural pressure gradient, TPG) were extracted. Validation was performed using empirical cumulative distribution function (ECDF) analysis, with an acceptance threshold of 5% for model credibility. EOA and TPG predictions showed reasonable agreement with echocardiographic data (errors within 10%). ECDF-based comparison demonstrated a high level of accuracy for device diameters (≤5% area metric), whereas hemodynamic parameters exhibited slightly greater discrepancies, potentially due to clinical measurement variability. This study establishes a robust computational validation framework for patient-specific TAVI modeling, ensuring regulatory compliance and clinical applicability. These findings highlight the potential of in silico trials to support TAVI planning and decision-making. This study is complemented by a second part dedicated to uncertainty quantification and sensitivity analysis.
Transcatheter aortic valve implantation (TAVI) benefits from patient-specific computational modeling, yet model credibility remains a challenge. The ASME V&V40 standard provides a framework for assessing uncertainty and sensitivity in in silico predictions, ensuring reliability in clinical decision-making. This study evaluates uncertainty quantification (UQ) and sensitivity analysis of a patient-specific TAVI model using the ASME V&V40 standard to enhance model credibility. Four patient-specific TAVI models with 23 and 26 mm SAPIEN 3 Ultra (S3) devices were developed using finite-element simulations for deployment and fluid–structure interaction analysis for hemodynamic analysis. Uncertain parameters included anatomical features, material properties, hemodynamic conditions, and procedural variables. A surrogate model was constructed with Gaussian-process regression, and probabilistic assessment was conducted via quasi-Monte Carlo analysis. Sensitivity analysis identified key parameters influencing model outputs. The surrogate model accurately predicted device diameter (mean relative error <1%), with balloon expansion volume and stent-frame material properties being the most influential. Hemodynamic predictions exhibited greater uncertainty, with effective orifice area and pressure gradient showing deviations beyond the 5% validation threshold. This study establishes a framework for UQ in patient-specific TAVI modeling, demonstrating reliable device deployment predictions. The findings support integrating in silico models into clinical decision-making, benefiting clinicians, manufacturers, and regulatory bodies. This study is complemented by a first part dedicated to the discrete validation of the patient-specific TAVI model against clinical data.
Background: This study aims to evaluate the cardiopulmonary effects of sacubitril/valsartan therapy in patients with heart failure with reduced ejection fraction (HFrEF), investigating a possible correlation with the degree of myocardial fibrosis, as assessed by cardiac magnetic resonance. Methods: A total of 134 outpatients with HFrEF were enrolled. Results: After a mean follow-up of 13.3 ± 6.6 months, an improvement in ejection fraction and a reduction in E/A ratio, inferior vena cava size and N-terminal pro-B-type natriuretic peptide levels were observed. At follow-up, we observed an increase in VO2 peak of 16% (p34 (OR 3.98; 95% CI [1.59–10.54]; p=0.0028); ventilatory oscillatory pattern (OR 4.65; 95% CI [1.55–16.13]; p=0.0052); and haemoglobin level (OR 0.35; 95% CI [0.21–0.55]; p4.6% was detected, a lower response after sacubitril/valsartan therapy was observed as expressed by improvement in ΔVO2 peak, O2 pulse, LVEF and N-terminal pro-B-type natriuretic peptide. No significant differences were observed in ΔVO2/Δ work and VE/VCO2 slope. Conclusion: Sacubitril/valsartan improves cardiopulmonary functional capacity in HFrEF patients. The presence of myocardial fibrosis on cardiac magnetic resonance is a predictor of response to therapy.